Lancet Commission on Hearing Loss-CTSA Administrative Supplement

柳叶刀听力损失委员会-CTSA 行政补充

• 批准号: 10190037
• 负责人: Leigh E Boulware
• 金额: $ 58.15万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-13 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10190037
• 关键词: Achievement; Address; Administrative Supplement; Age; Arts; Businesses; Childhood; Clinical; Clinical Sciences; Clinical and Translational Science Awards; Collaborations; Communities; Decision Making; Decision Modeling; Dementia; Development; Discipline of Nursing; Diverse Workforce; Educational Status; Engineering; Faculty; Federal Government; Fostering; Funding; Geographic Locations; Goals; Government; Health; Health Benefit; Healthcare Systems; Hearing problem; Industry; Infrastructure; Institutes; Institution; Intervention Studies; Language Development; Life; Methods; Mission; Multi-Institutional Clinical Trial; National Institute on Aging; National Institute on Deafness and Other Communication Disorders; Outcome Measure; Patients; Phase; Policy Maker; Prevention; Process; Publishing; Recommendation; Reporting; Research; Research Personnel; Resource Sharing; Resources; Science; Team Process; Translational Research; Translations; Trust; United States; United States National Institutes of Health; Universities; World Health Organization; cost-effectiveness evaluation; experience; hearing impairment; hearing loss treatment; improved; innovation; medical schools; multidisciplinary; novel strategies; population health; programs; skills

The mission of the Duke Clinical and Translational Science Institute is to catalyze the translation of scientific discoveries into population health benefits through collaborative research. With previous Clinical and Translational Science Award (CTSA) funding, we have successfully developed infrastructure and provided resources to support investigators across the clinical and translational scientific and workforce spectrums. Our achievements have facilitated high-impact discoveries, increased research efficiency, and nurtured a more capable and diverse workforce. We have also ignited a new era of collaborative science at Duke. Several new transdisciplinary programs have been launched, connecting trainees and faculty from our Schools of Medicine, Nursing, Engineering, Business, and Arts and Sciences to enhance translation. In the next phase, Duke proposes to capitalize on new opportunities with three broad initiatives. First, we will optimize clinical and translational science national networks’ methods and processes. Building on Duke’s leading experience coordinating multi-center clinical trials including its national Duke-Vanderbilt NCATS Trial Innovation Center, we will develop methods to optimize ‘local hub,’ ‘hub-to-network’ and ‘network-to-network’ processes for the NCATS Trial Innovation Network. We will also help investigators leverage a number of additional NIH network resources and provide methods to disseminate best practices throughout the CTSA network. Second, we will deepen, nurture, and extend stakeholder collaborations. We will strengthen existing partnerships and foster new ones with stakeholders at both the institutional and investigator levels. Partnerships and programs will expand the breadth and transparency of CTSI activities. We will also support investigators’ greater engagement with a broad range of patients, community groups, clinicians, health care systems, industry, venture capitalists, payers, policy makers, and others. Third, we will catalyze further science integration at Duke. An invigorated professional workforce will facilitate major transdisciplinary science initiatives. A new University-wide coordination infrastructure will further amplify collaboration and bridge science siloes. We will also support teams by improving their skills in team science, studying team processes, and by promoting the recognition of team contributions at our institution. Collectively, these activities will amplify the innovation and impact of our research nationally, regionally, and locally. We will measure outcomes that reflect improvement in the translation of discoveries, use of national best practices, institutional and investigator teamwork, research transparency, and community trust. We will share all best practices with the CTSA network. We believe our achievements will meaningfully enhance the impact of clinical and translational science on health across the United States. The following proposal is for an Administrative Supplement to the CTSA to support the Lancet Commission on Hearing Loss.

杜克临床和转化科学研究所的使命是催化 通过协作研究对人口健康的科学发现。与以前的临床 和翻译科学奖（CTSA）资金，我们成功地开发了基础设施和 提供资源来支持整个临床和翻译科学和劳动力的研究人员 频谱。我们的成就已经制定了高影响的发现，提高了研究效率，并且 培养一个更有能力的潜水者。我们还点燃了一个合作科学的新时代 在杜克。已经启动了几个新的跨学科计划，连接学员和教职员工 从我们的医学，护理，工程，商业以及艺术和科学学院来增强 翻译。在下一个阶段，杜克大学提议利用新的机会，三个广泛 倡议。首先，我们将优化临床和翻译的科学国家网络方法，并 过程。以杜克大学领先的经验为基础建立坐标，包括其多中心临床试验 国家杜克·范德比尔特NCATS试用创新中心，我们将开发优化“本地枢纽”的方法 NCATS试用创新网络的“集线器到网络”和“网络到网络”过程。我们也会 帮助调查人员利用许多其他NIH网络资源，并为 在整个CTSA网络中传播最佳实践。其次，我们将加深，护理和扩展 利益相关者的合作。我们将加强现有合作伙伴关系，并通过 机构和调查员级别的利益相关者。伙伴关系和计划将扩大 CTSI活动的广度和透明度。我们还将支持调查人员的更多参与 广泛的患者，社区团体，临床医生，卫生保健系统，行业，风险投资 资本家，付款人，政策制定者等。第三，我们将催化杜克大学的进一步科学融合。 充满活力的专业劳动力将支持主要的跨学科科学计划。一个新 全大学协调基础设施将进一步扩大合作和桥梁科学孤岛。我们 还将通过提高团队科学技能，学习团队流程以及通过 促进我们机构对团队贡献的认可。总的来说，这些活动将放大 我们在全国，地区和本地研究的创新和影响。我们将衡量结果 这反映了发现的翻译，国家最佳实践，机构和 研究者团队合作，研究透明度和社区信任。我们将与 CTSA网络。我们认为，我们的成就将有意义地增强临床的影响 全美的健康转化科学。以下建议是用于行政 补充CTSA，以支持柳叶刀委员会的听力损失。